Navigation Links
Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
Date:7/2/2008

Boston Scientific only company to offer choice of two distinct drugs on

separate drug-eluting stent platforms

NATICK, Mass., July 2 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved the PROMUS(TM) Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease. The PROMUS Stent is a private-labeled XIENCE(TM) V Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific under an agreement executed prior to the 2006 acquisition of the former Guidant Corporation by Boston Scientific. FDA approval clears the way for Boston Scientific to launch the PROMUS Stent immediately in the U.S.

The PROMUS Stent expands Boston Scientific's drug-eluting stent (DES) portfolio, which includes the TAXUS(R) Express2(R) Paclitaxel-Eluting Coronary Stent System (in the U.S. and international markets) and the TAXUS(R) Liberte(R) Paclitaxel-Eluting Coronary Stent System (in international markets), making Boston Scientific the only company to offer physicians the choice of two distinct drugs (paclitaxel and everolimus) on separate DES platforms.

"The PROMUS Stent has shown outstanding deliverability, low late loss and the potential to reduce the need for re-interventions," said Ted Feldman, M.D., F.S.C.A.I., Director of the Cardiac Catheterization Laboratory at Evanston Northwestern Healthcare in Evanston, Illinois. "These benefits will make the PROMUS Stent an attractive new treatment option for U.S. physicians and their patients."

"FDA approval of the PROMUS Stent fulfills Boston Scientific's promise of an unprecedented two-drug strategy - two distinct drugs o
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
4. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. Boston Scientific Announces Election of Ray Elliott to Its Board of Directors
7. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
8. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
9. Genzyme Begins Major Expansion of Boston Manufacturing Facility
10. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
11. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  KemPharm, Inc., a clinical-stage specialty pharmaceutical company ... new molecular entity (NME) prodrugs, announced today that ... issued U.S. Patent No. 8,816,083 to KemPharm for ... Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydromorphone, ... The patent, which extends through 2032, provides ...
(Date:9/30/2014)... 2014 iLab Solutions announced the results ... which focuses on core facility operations, growth and ... face today. , In its 4th year running, a ... is the year-over-year decrease in the percentage of revenue ... be feeling the constraints of this trend. When asked, ...
(Date:9/30/2014)... Lyme Research Alliance (LRA), the nation’s ... universities, today announced the awarding of seven grants worth ... cure for Lyme and other tick-borne diseases. , ... its history—over 20 grant proposals—a 100 percent increase from ... receive so many solid applications from talented scientists this ...
(Date:9/30/2014)... On September 11, Pharma IQ conducted an interview ... a session that he will lead on “Stem Cells” at ... 17-18, 2015 in London. In the interview posted ... to respond to several questions on the current state of ... cell toxicity, and future trends in the use of stem ...
Breaking Biology Technology:KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4
... Net Revenues - a record $35.5 million vs. $24.7 million in Q2 2007 ... - an increase of 43.4%, Q2 2008 Diluted Net Income per Share ... ... in Q2 2007 Q2 2008 New Bookings of $49.0 million vs. $34.5 million in Q2 ...
... F. Finn, Jr.,C.P.A. ("Finn") announced today that the assets ... July 28, 2008 for the benefit of,creditors. An Assignment ... wherein Finn will liquidate the assets, which consist primarily,of ... on October 10, 2008., Persons interested in bidding ...
... to be Called Kowa Pharmaceuticals America, ... Kowa,Company, Ltd., a privately-held company headquartered ... ProEthic Pharmaceuticals, Inc., a,privately-held specialty pharmaceutical company ... 2008, ProEthic will change name to Kowa,Pharmaceuticals ...
Cached Biology Technology:eResearchTechnology Reports Second Quarter 2008 Results 2eResearchTechnology Reports Second Quarter 2008 Results 3eResearchTechnology Reports Second Quarter 2008 Results 4eResearchTechnology Reports Second Quarter 2008 Results 5eResearchTechnology Reports Second Quarter 2008 Results 6eResearchTechnology Reports Second Quarter 2008 Results 7eResearchTechnology Reports Second Quarter 2008 Results 8eResearchTechnology Reports Second Quarter 2008 Results 9Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc. 2
(Date:9/29/2014)... University of Illinois scientists have found compounds that boost ... in a pretty unlikely placethe crushed seeds left after ... fuel. , "The bioactive compounds in Camelina sativa ... a mixture of phytochemicals that work together synergistically ... is a promising nutritional supplement because its bioactive ingredients ...
(Date:9/29/2014)... 2014Research!America,s 19th annual Advocacy Awards ... trailblazers in advancing medical progress to improve the ... event will take place on Wednesday, March 11, ... Washington, DC. , The 2015 Advocacy Award winners ... Michael Milken, founder of the Milken Institute and ...
(Date:9/29/2014)... Department of Energy Joint Genome Institute (DOE JGI), ... announced that 32 new projects have been selected ... sampling Antarctic lakes to Caribbean waters, and from ... water table in forested watersheds, the CSP 2015 ... science can be extracted. , "These projects ...
Breaking Biology News(10 mins):New way to detox? 'Gold of Pleasure' oilseed boosts liver detoxification enzymes 2Research!America to honor leaders in medical and health research advocacy 2Research!America to honor leaders in medical and health research advocacy 3Research!America to honor leaders in medical and health research advocacy 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 32015 DOE JGI's science portfolio delves deeper into the Earth's data mine 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 52015 DOE JGI's science portfolio delves deeper into the Earth's data mine 62015 DOE JGI's science portfolio delves deeper into the Earth's data mine 72015 DOE JGI's science portfolio delves deeper into the Earth's data mine 82015 DOE JGI's science portfolio delves deeper into the Earth's data mine 9
... WHO: The American Association of Pharmaceutical Scientists (AAPS) ... members employed in industry, academia, government and other ... a dynamic international forum for the exchange of ... public health. AAPS offers timely scientific programs, on-going ...
... the best way to keep the good bacteria in your ... vitamins, it,s best to get the bacteria you need from ... supplements, says Gail Cresci, Medical College of Georgia dietitian and ... is probably not even helping them and could potentially hurt ...
... is available in French . , Montreal, ... distinguishing between emotions, especially fear and disgust, according to a ... Neuropsychologia . As part of the investigation, Olivier Collignon ... recherche en neuropsychologie et cognition (CERNEC) demonstrated that women are ...
Cached Biology News:Eating right, not supplements, is best at keeping your good bacteria healthy, dietitian says 2Eating right, not supplements, is best at keeping your good bacteria healthy, dietitian says 3Women outperform men when identifying emotions 2Women outperform men when identifying emotions 3
...
HistoScan AP Universal Goat Kit...
Interact with both DNA and RNA; fluorescence green (Em=525 nm) bound to DNA; and fluorescence red (Em=~650 nm) bound to RNA....
One bottle containing 30 ml of protein solution and 0.1% sodium azide....
Biology Products: